Quick Facts: Factive (Gemifloxacin)

Primary Uses	Therapeutic Domain
Pneumonia	Mild-to-moderate community-acquired respiratory infection
Bronchitis	Acute bacterial exacerbation of chronic bronchitis

---

Factive (gemifloxacin) is a prescription-only medication indicated for the management of specific bacterial infections. Its primary role involves providing a therapeutic option for patients diagnosed with community-acquired pneumonia (CAP) of mild to moderate severity. CAP is a respiratory tract infection acquired outside of a hospital setting, which is caused by susceptible microorganisms.

This medication is also a relevant therapeutic option for the management of acute bacterial exacerbation of chronic bronchitis (ABECB). ABECB is a sudden worsening of symptoms in individuals with chronic bronchitis, often requiring intervention to address the bacterial component. The use of Factive for ABECB is typically reserved for situations where other treatment options are not suitable. The prescribing decision, including whether Factive is appropriate for the individual's specific bacterial infection, is always determined by a qualified healthcare professional.

Regulatory References

1. MedlinePlus guidance on gemifloxacin

Who Can and Cannot Use Factive? Official Eligibility

Official regulatory documents strictly define the populations eligible to use Factive (Gemifloxacin), an antibiotic available only to adults (18 years and older). Its safety and effectiveness have not been established in children or adolescents.

Factive is contraindicated and must not be used in patients with a known history of hypersensitivity to gemifloxacin, any fluoroquinolone antibiotic, or any component of the medication. It is also prohibited for patients with a known history of Myasthenia Gravis.

Eligibility is restricted or conditional based on underlying health status:

• Severe Renal Impairment: Patients with creatinine clearance CrCl le 40 mL/min are eligible but require a mandated dose modification.
• Cardiovascular Conditions: Factive should be avoided in patients with a history of prolonged QTc interval or uncorrected electrolyte disorders (like hypokalemia or hypomagnesemia).
• Pregnancy and Lactation: Use is not established in pregnant or nursing women.

Population Group	Eligibility Status
Pediatric (Under 18)	Not established
Hypersensitivity	Contraindicated
Myasthenia Gravis	Contraindicated
Severe Kidney Impairment	Use restricted (dose modification)

Factive Interactions with other medicines and products

This section details only the officially documented interaction patterns for Factive (gemifloxacin) as established by government regulatory bodies.

Formal Contraindicated Combinations

Factive is contraindicated for co-administration with certain drugs due to the documented risk of QTc interval prolongation. This includes Class IA Antiarrhythmics (e.g., quinidine, procainamide) and Class III Antiarrhythmics (e.g., amiodarone, sotalol), as well as other medicinal products known to prolong the QTc interval (e.g., thioridazine, pimozide).

---

Interactions with Cation-Containing Products

The systemic availability of gemifloxacin is significantly reduced when taken with products containing di- and trivalent metal cations, which chelate the antibiotic and reduce its absorption. These include aluminum- and/or magnesium-containing antacids, ferrous sulfate (Iron), zinc-containing multivitamin preparations, Sucralfate, and Didanosine buffered formulations.

To mitigate this reduction in exposure, regulatory guidance mandates specific timing separation:

• Cation-containing antacids, iron, zinc supplements, and Didanosine must not be taken within 3 hours before or 2 hours after Factive.
• Sucralfate should be taken at least 2 hours after Factive.

---

Other Pharmacodynamic Cautions

Co-administration with corticosteroids increases the risk of tendinitis and tendon rupture, especially in patients over 60 years of age or those with transplants. Concurrent use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of CNS effects. Factive may be taken without regard to meals.

Factive (Gemifloxacin) functions as a bactericidal agent by interfering with the ability of bacteria to manage their genetic material and divide.

---

Dual-Targeted Enzyme Inhibition and DNA Poisoning

The mechanism relies on simultaneous inhibition of two critical bacterial enzymes: DNA Gyrase and Topoisomerase IV. The drug acts as a "poison," binding to and stabilizing the complex where these enzymes have cut the DNA strands. This action prevents the enzymes from repairing the cuts, resulting in a cascade that induces multiple, irreparable double-stranded DNA breaks throughout the bacterial genome. This mechanism engages systems where targeted enzyme adjustment is required, resulting in the accumulation of cytotoxic genetic lesions.

---

Cessation of Replication and Bactericidal Effect

The severe genetic damage, coupled with the inability of Topoisomerase IV to complete chromosome separation, causes the cessation of bacterial DNA replication and cell division. This mechanistic cascade leads directly to cell death, which is the core physiological consequence. This effect, resulting in cell death (bactericidal), contrasts with agents that only inhibit growth (bacteriostatic).

Instruction Map: How to use Factive

Instruction Category	Guideline
Route of Administration	Oral ingestion as a film-coated tablet.
Dosing Schedule	Standard Adult Dose: One 320 mg tablet once daily. Adjusted Dose: 160 mg once daily for patients with renal impairment (creatinine clearance CrCl le 40 mL/min).
Timing in relation to meals	May be administered without regard to meals.
Preparation requirements	The tablet must be swallowed whole with liquid; no crushing or chewing.
Age-group administration rules	Older Adults and those with Hepatic Impairment require no dosage adjustment. Use in patients under 18 years is not established.
Special procedural conditions	The tablet must be taken at least 2 hours before or 3 hours after products that contain metal cations (e.g., antacids, iron, or zinc supplements).

---

Instruction Classifications (High-level)

Classification	Pattern
Administration method type	Oral.
Frequency pattern	Once daily (q24h).
Use-context constraints	Duration-fixed (5 or 7 days); Dosing is Renal-function dependent for specific populations.

---

Resulting Procedural Structure

Course Duration:

• Treatment for Acute Bacterial Exacerbation of Chronic Bronchitis is 5 days.
• Treatment for Community-Acquired Pneumonia (CAP) is 5 days for most susceptible strains and 7 days for infections caused by multi-drug resistant S. pneumoniae.

Connection to the overall use protocol: The standardized protocol for Factive defines a once-daily oral dose that is either 320 mg or 160 mg, determined by the patient's renal function. The protocol establishes a fixed treatment duration linked to the diagnosed condition, along with specific timing constraints for co-administration with mineral supplements. This structure ensures adherence to the established parameters for the medication's administration.

Research Evidence / Overview of Studies

Mechanism and Acute Infection Research

Clinical research has evaluated the compound's activity as a fluoroquinolone antibiotic with studies examining its use against specific bacterial infections. The compound was studied in the context of treating respiratory tract and skin structure infections, among others.

Area of Research	Key Finding Reported	Patient Population Studied
Community-Acquired Pneumonia (CAP)	Studies reported non-inferiority against certain comparator antibiotics, with a clinical success rate ranging from 89% to 95%.	Adults with mild-to-moderate CAP.
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)	Clinical trials reported resolution of infection signs and symptoms in the majority of subjects.	Adults with a history of chronic obstructive pulmonary disease (COPD).

Tolerability and Pharmacokinetics

A key meta-analysis evaluated the compound’s tolerability profile in adult populations. The most commonly reported adverse events across the pooled data were gastrointestinal discomfort and rash. Serious, though rare, adverse events typical of the fluoroquinolone class, such as tendon rupture and central nervous system effects, were monitored across the studies.

Studies have evaluated the compound’s absorption when administered, noting that it is well absorbed after oral intake. Peak plasma concentrations are typically achieved within one to two hours. Further research has explored the evaluation of different dosing schedules and durations of treatment, which are dependent on the specific infection being studied.

Research in Specific Populations

Research has examined the compound’s use in patients with compromised kidney function. Adjustment to the dose or dosing interval was found to be necessary for subjects with severe kidney impairment to manage the compound’s concentration in the body. Research has also investigated the use of the compound in populations with liver impairment, where no dose adjustment was typically required.

Common questions about Factive (FAQ)

Q: How quickly does Factive start to work after I begin taking it?

A: Regulatory pharmacokinetic data indicates that the peak concentration of the active ingredient in the bloodstream is typically observed between 0.5 and 2 hours after the tablet is taken. This concentration aligns with the time frame related to the drug’s intended action.

---

Q: Can Factive affect my sleep or cause insomnia?

A: Official prescribing information reports that central nervous system (CNS) effects, including trouble sleeping or insomnia, have been listed among the serious adverse reactions. The main safety section contains guidance on these reactions.

---

Q: Does Factive interact with common pain relievers like ibuprofen?

A: Regulatory documents state that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of central nervous system (CNS) effects. NSAIDs include common pain relievers.

---

Q: Are there any known interactions between Factive and supplements or vitamins?

A: The systemic availability of the active ingredient is reduced when taken with supplements containing metal cations, such as iron or zinc. Official instructions mandate a specific time separation for taking these cation-containing products.

---

Q: What foods or drinks should be avoided while on Factive?

A: Factive may be administered without regard to meals; that is, it can be taken with or without food. However, the product must be taken separated by specific time intervals from products containing metal cations, such as certain antacids and iron supplements, as these can reduce the amount of antibiotic absorbed.

---

Q: Can older adults (seniors) use Factive safely?

A: Official documents state that no dosage adjustment is typically required for older adults. However, patients over 60 years of age are specifically identified as having an increased risk of tendinitis and tendon rupture, a warning detailed in the official Boxed Warning.

---

Q: What should I do if I experience a rash while taking Factive?

A: While rash is reported as a common adverse reaction, official safety guidance indicates that the drug should be discontinued immediately at the appearance of any sign of an immediate type I hypersensitivity skin rash. The instruction to discontinue the drug applies to any manifestation of a hypersensitivity reaction.

---

Q: What is the success rate of Factive in clinical studies?

A: Studies and official information indicate that clinical trials reported a success rate ranging from 89% to 95% in the treatment of Community-Acquired Pneumonia (CAP). For Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), trials reported resolution of infection signs and symptoms in the majority of subjects.

---

Q: Can Factive be used if I have a history of seizures?

A: Factive may lower the seizure threshold as it belongs to the fluoroquinolone class. Regulatory documents note that caution is advised for patients with known or suspected CNS disorders that may predispose them to seizures.

---

Q: What are the restrictions on driving or operating machinery while taking Factive?

A: Because Factive can cause dizziness and other Central Nervous System effects (like confusion), official regulatory guidance contains a warning against driving or operating heavy machinery until it is known how the medication affects the individual.

---

Q: Are there studies comparing Factive's effectiveness to older antibiotics?

A: Clinical trials have reported that Factive demonstrated non-inferiority when compared to certain other established antibiotics for the treatment of its approved indications. The studies reported the drug was demonstrated to be non-inferior to the comparators.

---

Q: Is Factive associated with any long-term health effects?

A: The official Boxed Warning describes serious adverse reactions, such as peripheral neuropathy (nerve damage), that may be potentially irreversible. It also notes that tendon rupture can occur months after treatment is completed.

---

Q: Does Factive have any uses outside of treating bacterial infections?

A: Official documentation states Factive is an antibacterial drug that should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. It is not approved for use against viral infections.

---

Q: Is Factive considered a strong antibiotic?

A: Factive is classified as a fluoroquinolone antibiotic, which is a type of broad-spectrum antibacterial agent. It is described as a bactericidal agent, meaning its pharmacological role is to kill the targeted bacteria.

---

Q: What happens if I miss a dose of Factive?

A: If a dose is missed, official patient information advises taking it as soon as it is remembered, unless it is almost time for the next scheduled dose. Official information indicates that no more than one dose should be taken per day.

---

Q: Is Factive the same as Cipro or Levaquin?

A: Factive (gemifloxacin), Cipro (ciprofloxacin), and Levaquin (levofloxacin) are not the same medicine, but they all belong to the same pharmacological class of antibacterial drugs, known as fluoroquinolones.

---

Q: Can I drink coffee or caffeine while taking Factive?

A: Regulatory resources suggest that Factive is generally believed to have little or no effect on the enzyme that metabolizes caffeine. This means a clinically significant interaction with caffeine is not typically expected.

---

Q: Can Factive affect blood sugar levels?

A: As a member of the fluoroquinolone class, Factive has been associated with Blood Glucose Disturbances. These can include both high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia).

---

Q: Can Factive be taken if I am allergic to penicillin?

A: The official contraindication for Factive is a known history of hypersensitivity to gemifloxacin, other fluoroquinolones, or any component of the medication. Official documents do not list an allergy to penicillin as a contraindication.

---

Q: Does Factive treat viral infections like the flu?

A: Factive is a bactericidal agent, meaning its purpose is to kill bacteria. It is officially indicated only for the treatment of infections that are proven or strongly suspected to be caused by susceptible bacteria and is not effective against viral infections.

---

Q: Can Factive be used to treat STIs?

A: Factive is officially indicated only for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis and Community-Acquired Pneumonia in adults. It is not listed as an approved treatment for sexually transmitted infections (STIs).

---

Q: What is the likelihood of getting a C. difficile infection after taking Factive?

A: A more serious form of diarrhea with inflammation of the colon, known as pseudomembranous colitis and often linked to Clostridium difficile, has been reported with Factive. This adverse effect is a known risk associated with most antibiotics.

---

Q: Does Factive affect birth control pills?

A: Official regulatory labeling does not specifically document a major interaction between Factive and hormonal contraceptives. No significant drug-specific interaction is noted in the labeling.

---

Q: Why do official documents mention Factive is only for certain infections?

A: Regulatory documents emphasize that Factive should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. This restriction is a measure used to help reduce the development of drug-resistant bacteria.

---

Q: Is Factive available as a generic drug?

A: Gemifloxacin, the active ingredient in Factive, is available in generic form. Generic and brand-name drugs must meet the same federal standards for quality and purity.

---

Q: What are the main things I should discuss with my healthcare provider before starting Factive?

A: Regulatory documents highlight pre-existing conditions and concurrent medications to discuss, such as a history of Myasthenia Gravis, a known prolonged QTc interval, pre-existing kidney impairment, and the use of corticosteroids. These factors are relevant to the determination of eligibility and risk of serious adverse reactions.

---

Q: How can I tell the difference between a normal side effect and a serious one while using Factive?

A: Official safety information lists signs of serious adverse reactions, such as pain/swelling in tendons, numbness/tingling in limbs (peripheral neuropathy), or seizures/hallucinations (CNS effects). The information indicates that the drug should be stopped immediately if these serious symptoms occur.

---

Q: What does the term 'fluoroquinolone' mean regarding Factive?

A: Fluoroquinolone is the class of antibacterial drug that Factive belongs to. This classification identifies it as a synthetic drug that acts as a bactericidal agent by interfering with the bacteria’s ability to manage and copy its own genetic material.

---

Q: Why is Factive considered a 'reserve' antibiotic by some sources?

A: Official regulatory documents advise reserving Factive for use in patients who have no alternative treatment options for Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB). This policy is aimed at promoting appropriate antimicrobial stewardship.

---

Q: What happens if Factive is taken with dairy products?

A: Factive is affected by products containing metal cations, which reduce its absorption. Dairy products contain calcium, a divalent cation, and official instruction requires specific time separation from all metal cation-containing products.

Storage and Disposal of Factive (Gemifloxacin)

Factive tablets must be stored at controlled room temperature, specifically between 68 F to 77 F (20 C to 25 C). The medication should be kept in a closed container and protected from moisture, direct light, and excessive heat. It is mandatory that Factive is not frozen and is stored out of the reach of children.

Disposal

For unused or expired medicine, the preferred method of disposal is through drug take-back locations or prepaid mail-back envelopes. If these options are unavailable, the FDA advises mixing the medicine with an unappealing substance, placing it in a sealed bag, and discarding it in the household trash. The medication must not be flushed down the toilet.